-transparent.png){kind=logo}
The plasma protein binding of diphenylhydantoin sodium was determined in 26 patients who had been taking diphenylhydantoin regularly for more than two weeks. The free (unbound) diphenylhydantoin level was found to vary from 5.8% to 12.6% of the total drug concentration. This range of variation may be clinically important, if it can be established that the binding of diphenylhydantoin to plasma proteins limits entry of the drug into the brain. The binding of diphenylhydantoin was directly proportional to the plasma albumin concentration, which thus appeared to be the most important determinant of diphenylhydantoin binding. Diphenylhydantoin binding was independent of the plasma concentration of the drug in the usual therapeutic range. In vitro studies showed little effect by phenobarbital sodium or penicillin G; therapeutic levels of acetylsalicylic acid, however, increased free diphenylhydantoin by nearly 50%.
R J Porter, and
R B Layzer
May 1975,
Klinische Wochenschrift,
R J Porter, and
R B Layzer
January 1971,
Acta pharmacologica et toxicologica,
R J Porter, and
R B Layzer
July 1971,
Annals of the New York Academy of Sciences,
R J Porter, and
R B Layzer
January 1970,
Acta pharmacologica et toxicologica,
R J Porter, and
R B Layzer
January 1970,
Acta pharmacologica et toxicologica,
R J Porter, and
R B Layzer
September 1974,
Harefuah,
R J Porter, and
R B Layzer
October 1975,
The Journal of pharmacology and experimental therapeutics,
R J Porter, and
R B Layzer
September 1977,
Bollettino della Societa italiana di biologia sperimentale,
R J Porter, and
R B Layzer
August 1974,
Clinical pharmacology and therapeutics,
R J Porter, and
R B Layzer
January 1970,
Clinical pharmacology and therapeutics,
